CN113329753B - 用于预防和治疗革兰氏阴性细菌感染、污染和污垢的新型嘧啶衍生物 - Google Patents

用于预防和治疗革兰氏阴性细菌感染、污染和污垢的新型嘧啶衍生物 Download PDF

Info

Publication number
CN113329753B
CN113329753B CN202080010314.3A CN202080010314A CN113329753B CN 113329753 B CN113329753 B CN 113329753B CN 202080010314 A CN202080010314 A CN 202080010314A CN 113329753 B CN113329753 B CN 113329753B
Authority
CN
China
Prior art keywords
sch
nhch
difluorophenyl
nch
cyclopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080010314.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN113329753A (zh
Inventor
帕特里齐奥·兰切洛蒂
塞西尔·乌里
贝尔纳·皮罗特
露西娅·穆苏梅西
尼古拉斯·雅克
埃里克·戈芬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Liège
Original Assignee
University of Liège
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Liège filed Critical University of Liège
Publication of CN113329753A publication Critical patent/CN113329753A/zh
Application granted granted Critical
Publication of CN113329753B publication Critical patent/CN113329753B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/713—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with four or more nitrogen atoms as the only ring hetero atoms
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Prostheses (AREA)
CN202080010314.3A 2019-04-18 2020-04-17 用于预防和治疗革兰氏阴性细菌感染、污染和污垢的新型嘧啶衍生物 Active CN113329753B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19170003 2019-04-18
EP19170003.8 2019-04-18
EP19188639.9 2019-07-26
EP19188639 2019-07-26
PCT/EP2020/060819 WO2020212553A1 (en) 2019-04-18 2020-04-17 New pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling

Publications (2)

Publication Number Publication Date
CN113329753A CN113329753A (zh) 2021-08-31
CN113329753B true CN113329753B (zh) 2024-08-13

Family

ID=70480222

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080010314.3A Active CN113329753B (zh) 2019-04-18 2020-04-17 用于预防和治疗革兰氏阴性细菌感染、污染和污垢的新型嘧啶衍生物

Country Status (10)

Country Link
US (1) US12318388B2 (cg-RX-API-DMAC7.html)
EP (1) EP3955929B1 (cg-RX-API-DMAC7.html)
JP (1) JP7588859B2 (cg-RX-API-DMAC7.html)
KR (1) KR102857084B1 (cg-RX-API-DMAC7.html)
CN (1) CN113329753B (cg-RX-API-DMAC7.html)
AU (1) AU2020258017B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021012834A2 (cg-RX-API-DMAC7.html)
DK (1) DK3955929T3 (cg-RX-API-DMAC7.html)
ES (1) ES2981773T3 (cg-RX-API-DMAC7.html)
WO (1) WO2020212553A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3527571A1 (en) * 2018-02-14 2019-08-21 Université de Liège Pyrimidine derivatives for prevention and treatment of bacterial infection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111386271A (zh) * 2018-02-14 2020-07-07 列日大学 用于预防和治疗细菌感染的嘧啶衍生物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4928399A (en) * 1998-07-27 2000-02-21 M & M Laboratory Co., Ltd. Ion complex, coating material, and coating method
WO2004021979A2 (en) * 2002-09-06 2004-03-18 Smithkline Beecham Corporation PYRROLO[2, 3-d]PYRIMIDINE-4-YL AND PURIN-6-YL UREA COMPOUNDS
DE102005060690B4 (de) * 2005-12-15 2008-09-25 Capsulution Nanoscience Ag Salze von Clopidogrel mit Polyanionen und ihre Verwendung zur Herstellung pharmazeutischer Formulierungen
WO2009034386A1 (en) 2007-09-13 2009-03-19 Astrazeneca Ab Derivatives of adenine and 8-aza-adenine and uses thereof-796
EP2236158A1 (en) * 2009-03-30 2010-10-06 Pharnext New therapeutic approaches for treating neuroinflammatory conditions
WO2010118367A2 (en) * 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
ES2731658T3 (es) 2016-09-09 2019-11-18 Univ Liege Derivados triazolo(4,5-d)pirimidina para uso en la prevención y tratamiento de infección bacteriana
GB201910656D0 (en) 2019-07-25 2019-09-11 Univ Liege New use of triazolo(4,5-d)Pyrimidine deerivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111386271A (zh) * 2018-02-14 2020-07-07 列日大学 用于预防和治疗细菌感染的嘧啶衍生物

Also Published As

Publication number Publication date
KR102857084B1 (ko) 2025-09-10
BR112021012834A2 (pt) 2021-09-28
JP7588859B2 (ja) 2024-11-25
DK3955929T3 (da) 2024-08-05
US20210290625A1 (en) 2021-09-23
WO2020212553A1 (en) 2020-10-22
AU2020258017A1 (en) 2021-07-01
KR20220003556A (ko) 2022-01-10
ES2981773T3 (es) 2024-10-10
JP2022529052A (ja) 2022-06-16
CN113329753A (zh) 2021-08-31
AU2020258017B2 (en) 2025-05-29
EP3955929B1 (en) 2024-05-15
US12318388B2 (en) 2025-06-03
CA3128304A1 (en) 2020-10-22
EP3955929A1 (en) 2022-02-23

Similar Documents

Publication Publication Date Title
CN111386271B (zh) 用于预防和治疗细菌感染的嘧啶衍生物
RU2626979C2 (ru) Трициклические ингибиторы гиразы
JP5657642B2 (ja) リバースターン類似体の新規な化合物およびその製造方法と用途
ES2545516T3 (es) Inhibidores de la pirimidina girasa y la topoisomerasa IV
KR101565971B1 (ko) 이소티아졸로피리미디논을 사용하는 신경 발생을 자극하고 신경 변성을 억제하는 방법 및 조성물
ES2705923T3 (es) Formas sólidas de inhibidor de girasa (R)-1-etil-3-[6-fluoro-5-[2-(1-hidroxi-1-metil-etil)pirimidin-5-il]-7-(tetrahidrofuran-2-il)-1H-bencimidazol-2-il]urea
JP2019502667A (ja) 抗菌化合物
US12318388B2 (en) Pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling
CA3128304C (en) Pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling
CA3090945C (en) Pyrimidine derivatives for prevention and treatment of bacterial infections
JPH04338331A (ja) γ−ラクトン免疫抑制剤
BR112020009290B1 (pt) Derivados de pirimidina, seu método de preparação e seu uso, composição farmacêutica, e método ex vivo para matar ou impedir o crescimento bacteriano na formação de biofilme
JP7354245B2 (ja) ピロロピリミジン骨格を有する新規なカーボネート化合物又はその薬学的に許容可能な塩
AU2013211455B2 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
HK1190150B (en) Pyrimidine gyrase and topoisomerase iv inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant